UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
기사
(전체 239건)
제목보기
제목보기
제목+내용
기사보기
Dong-A ST, Dongwha Pharm lose status of innovative drugmaker
Dong-A ST and Dongwha Ph...
Jeong Sae-im
|
2019-07-05 16:00
기사보기
Victims question Kolon CEO’s sincerity in apology
Oh Kims Law & Co., leadi...
Jeong Sae-im
|
2019-07-05 15:14
기사보기
Janssen nixes deal with Hanmi over antidiabetic obesity drug
Janssen, a subsidiary of...
Jeong Sae-im
|
2019-07-04 10:52
기사보기
[News Focus]Yuhan pulled off $3.1 billion licensing deals in one year. How?
Yuhan Corp. recently mad...
Jeong Sae-im
|
2019-07-02 12:11
기사보기
[Special]Korean drugmakers harbor undue expectations on global blockbusters
“The pharmaceutical and ...
Jeong Sae-im
|
2019-07-01 16:19
기사보기
BNO BIO to invest $1 million in Israeli biotech venture
BNO BIO, a joint venture...
Jeong Sae-im
|
2019-06-28 16:10
기사보기
Shareholders in shock over HLB’s phase-3 trial setback
Investors in HLB have ex...
Jeong Sae-im
|
2019-06-28 10:47
기사보기
‘Food and drug ministry alone can’t handle Invossa debacle’
“The National Medical Ce...
Jeong Sae-im
|
2019-06-27 12:45
기사보기
Patients with ‘Invossa stigma’ struggle to get treatment, insurance
“I received Invossa inje...
Jeong Sae-im
|
2019-06-26 13:22
기사보기
Oscotech wins exception policy for continued R&D for new drugs
The stock market regulat...
Jeong Sae-im
|
2019-06-25 14:11
기사보기
‘Customized strategies needed for fast-changing Chinese drug regulation’
Foreign drugmakers need ...
Jeong Sae-im
|
2019-06-21 14:12
기사보기
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting
Jeong Sae-im
|
2019-06-20 14:20
-
이전
11
12
13
14
15
16
17
18
19
20
-
Back to Top